The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Olaf Grisk
  • Torsten Schlüter
  • Nico Reimer
  • Uwe Zimmermann
  • Elpiniki Katsari
  • Oliver Plettenburg
  • Matthias Löhn
  • Hans Georg Wollert
  • Rainer Rettig

External Research Organisations

  • University of Greifswald
  • Karlsburg Hospital Heart and Diabetes Center Mecklenburg-Vorpommern
  • Sanofi-Aventis Deutschland GmbH
View graph of relations

Details

Original languageEnglish
Pages (from-to)980-989
Number of pages10
JournalJournal of hypertension
Volume30
Issue number5
Publication statusPublished - May 2012
Externally publishedYes

Abstract

Objectives: Increased renal vascular resistance contributes to the pathogenesis of hypertension. The new Rho kinase (ROCK) inhibitor SAR407899 more potently lowers arterial pressure than the commercially available ROCK inhibitor Y27623. We tested whether ROCK inhibition more effectively reduced agonist-induced vasoconstriction in renal than in nonrenal resistance arteries and if SAR407899 more potently inhibits agonist-induced vasoconstriction than Y27632. Methods: The effects of the ROCK inhibitors on endothelin-1 (ET-1) induced vasoconstriction were investigated in isolated renal and coronary arteries from lean, normotensive Dark Agouti and obese, type 2 diabetic Zucker diabetic fatty (ZDF) rats as well as in isolated human resistance arteries from the kidney and thymus. Vascular ROCK mRNA abundance was studied by real-time PCR (RT-PCR). Results: ET-1-induced constriction depended more on ROCK in rat and human renal resistance arteries than in rat coronary or human thymic arteries, respectively. SAR407899 was more effective than Y27632 in reducing ET-1-induced vasoconstriction in ZDF rat renal resistance arteries. Maximum ET-1-induced vasoconstriction in SAR407899-treated and Y27632-treated human renal resistance arteries was 23 ± 5 and 48 ± 6% of control values, respectively. Transcripts of both ROCK isoforms were detected in rat and human renal resistance arteries. In human thymic arteries, only the ROCK2 transcript was found. Conclusion: ET-1-induced vasoconstriction is more ROCK-dependent in renal than in nonrenal resistance arteries. SAR407899 causes a greater inhibition of ET-1-induced vasoconstriction in renal resistance arteries from ZDF rats and patients than Y27632. The greater efficacy in renal vessels may contribute to the higher antihypertensive potency of SAR407899 compared with Y27632.

Keywords

    antihypertensive agents, blood pressure, Rho kinase, vascular resistance, vascular smooth muscle

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. / Grisk, Olaf; Schlüter, Torsten; Reimer, Nico et al.
In: Journal of hypertension, Vol. 30, No. 5, 05.2012, p. 980-989.

Research output: Contribution to journalArticleResearchpeer review

Grisk, O, Schlüter, T, Reimer, N, Zimmermann, U, Katsari, E, Plettenburg, O, Löhn, M, Wollert, HG & Rettig, R 2012, 'The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries', Journal of hypertension, vol. 30, no. 5, pp. 980-989. https://doi.org/10.1097/HJH.0b013e328351d459
Grisk, O., Schlüter, T., Reimer, N., Zimmermann, U., Katsari, E., Plettenburg, O., Löhn, M., Wollert, H. G., & Rettig, R. (2012). The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. Journal of hypertension, 30(5), 980-989. https://doi.org/10.1097/HJH.0b013e328351d459
Grisk O, Schlüter T, Reimer N, Zimmermann U, Katsari E, Plettenburg O et al. The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. Journal of hypertension. 2012 May;30(5):980-989. doi: 10.1097/HJH.0b013e328351d459
Grisk, Olaf ; Schlüter, Torsten ; Reimer, Nico et al. / The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. In: Journal of hypertension. 2012 ; Vol. 30, No. 5. pp. 980-989.
Download
@article{c46c08fd02aa4916bfea59405143f422,
title = "The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries",
abstract = "Objectives: Increased renal vascular resistance contributes to the pathogenesis of hypertension. The new Rho kinase (ROCK) inhibitor SAR407899 more potently lowers arterial pressure than the commercially available ROCK inhibitor Y27623. We tested whether ROCK inhibition more effectively reduced agonist-induced vasoconstriction in renal than in nonrenal resistance arteries and if SAR407899 more potently inhibits agonist-induced vasoconstriction than Y27632. Methods: The effects of the ROCK inhibitors on endothelin-1 (ET-1) induced vasoconstriction were investigated in isolated renal and coronary arteries from lean, normotensive Dark Agouti and obese, type 2 diabetic Zucker diabetic fatty (ZDF) rats as well as in isolated human resistance arteries from the kidney and thymus. Vascular ROCK mRNA abundance was studied by real-time PCR (RT-PCR). Results: ET-1-induced constriction depended more on ROCK in rat and human renal resistance arteries than in rat coronary or human thymic arteries, respectively. SAR407899 was more effective than Y27632 in reducing ET-1-induced vasoconstriction in ZDF rat renal resistance arteries. Maximum ET-1-induced vasoconstriction in SAR407899-treated and Y27632-treated human renal resistance arteries was 23 ± 5 and 48 ± 6% of control values, respectively. Transcripts of both ROCK isoforms were detected in rat and human renal resistance arteries. In human thymic arteries, only the ROCK2 transcript was found. Conclusion: ET-1-induced vasoconstriction is more ROCK-dependent in renal than in nonrenal resistance arteries. SAR407899 causes a greater inhibition of ET-1-induced vasoconstriction in renal resistance arteries from ZDF rats and patients than Y27632. The greater efficacy in renal vessels may contribute to the higher antihypertensive potency of SAR407899 compared with Y27632.",
keywords = "antihypertensive agents, blood pressure, Rho kinase, vascular resistance, vascular smooth muscle",
author = "Olaf Grisk and Torsten Schl{\"u}ter and Nico Reimer and Uwe Zimmermann and Elpiniki Katsari and Oliver Plettenburg and Matthias L{\"o}hn and Wollert, {Hans Georg} and Rainer Rettig",
year = "2012",
month = may,
doi = "10.1097/HJH.0b013e328351d459",
language = "English",
volume = "30",
pages = "980--989",
journal = "Journal of hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "5",

}

Download

TY - JOUR

T1 - The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries

AU - Grisk, Olaf

AU - Schlüter, Torsten

AU - Reimer, Nico

AU - Zimmermann, Uwe

AU - Katsari, Elpiniki

AU - Plettenburg, Oliver

AU - Löhn, Matthias

AU - Wollert, Hans Georg

AU - Rettig, Rainer

PY - 2012/5

Y1 - 2012/5

N2 - Objectives: Increased renal vascular resistance contributes to the pathogenesis of hypertension. The new Rho kinase (ROCK) inhibitor SAR407899 more potently lowers arterial pressure than the commercially available ROCK inhibitor Y27623. We tested whether ROCK inhibition more effectively reduced agonist-induced vasoconstriction in renal than in nonrenal resistance arteries and if SAR407899 more potently inhibits agonist-induced vasoconstriction than Y27632. Methods: The effects of the ROCK inhibitors on endothelin-1 (ET-1) induced vasoconstriction were investigated in isolated renal and coronary arteries from lean, normotensive Dark Agouti and obese, type 2 diabetic Zucker diabetic fatty (ZDF) rats as well as in isolated human resistance arteries from the kidney and thymus. Vascular ROCK mRNA abundance was studied by real-time PCR (RT-PCR). Results: ET-1-induced constriction depended more on ROCK in rat and human renal resistance arteries than in rat coronary or human thymic arteries, respectively. SAR407899 was more effective than Y27632 in reducing ET-1-induced vasoconstriction in ZDF rat renal resistance arteries. Maximum ET-1-induced vasoconstriction in SAR407899-treated and Y27632-treated human renal resistance arteries was 23 ± 5 and 48 ± 6% of control values, respectively. Transcripts of both ROCK isoforms were detected in rat and human renal resistance arteries. In human thymic arteries, only the ROCK2 transcript was found. Conclusion: ET-1-induced vasoconstriction is more ROCK-dependent in renal than in nonrenal resistance arteries. SAR407899 causes a greater inhibition of ET-1-induced vasoconstriction in renal resistance arteries from ZDF rats and patients than Y27632. The greater efficacy in renal vessels may contribute to the higher antihypertensive potency of SAR407899 compared with Y27632.

AB - Objectives: Increased renal vascular resistance contributes to the pathogenesis of hypertension. The new Rho kinase (ROCK) inhibitor SAR407899 more potently lowers arterial pressure than the commercially available ROCK inhibitor Y27623. We tested whether ROCK inhibition more effectively reduced agonist-induced vasoconstriction in renal than in nonrenal resistance arteries and if SAR407899 more potently inhibits agonist-induced vasoconstriction than Y27632. Methods: The effects of the ROCK inhibitors on endothelin-1 (ET-1) induced vasoconstriction were investigated in isolated renal and coronary arteries from lean, normotensive Dark Agouti and obese, type 2 diabetic Zucker diabetic fatty (ZDF) rats as well as in isolated human resistance arteries from the kidney and thymus. Vascular ROCK mRNA abundance was studied by real-time PCR (RT-PCR). Results: ET-1-induced constriction depended more on ROCK in rat and human renal resistance arteries than in rat coronary or human thymic arteries, respectively. SAR407899 was more effective than Y27632 in reducing ET-1-induced vasoconstriction in ZDF rat renal resistance arteries. Maximum ET-1-induced vasoconstriction in SAR407899-treated and Y27632-treated human renal resistance arteries was 23 ± 5 and 48 ± 6% of control values, respectively. Transcripts of both ROCK isoforms were detected in rat and human renal resistance arteries. In human thymic arteries, only the ROCK2 transcript was found. Conclusion: ET-1-induced vasoconstriction is more ROCK-dependent in renal than in nonrenal resistance arteries. SAR407899 causes a greater inhibition of ET-1-induced vasoconstriction in renal resistance arteries from ZDF rats and patients than Y27632. The greater efficacy in renal vessels may contribute to the higher antihypertensive potency of SAR407899 compared with Y27632.

KW - antihypertensive agents

KW - blood pressure

KW - Rho kinase

KW - vascular resistance

KW - vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=84859893278&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e328351d459

DO - 10.1097/HJH.0b013e328351d459

M3 - Article

C2 - 22388233

AN - SCOPUS:84859893278

VL - 30

SP - 980

EP - 989

JO - Journal of hypertension

JF - Journal of hypertension

SN - 0263-6352

IS - 5

ER -

By the same author(s)